Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
Body unavailable. Use the original source.
Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.